Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06026514 · ClinicalTrials.gov registry record · Phase 1
Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT06026514 is a Phase 1 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 27 participants.
The verdict
NCT06026514, a Phase 1 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This Phase 1 clinical trial will evaluate the safety and immunogenicity of an intranasal vaccine candidate, a recombinant, live-attenuated, bovine/human parainfluenza virus vector vaccine expressing the 6-P prefusion-stabilized version of the SARS-CoV-2 spike protein.
Interventions
- BIOLOGICAL B/HPIV3/S-6P
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2023-09-18 |
| Est. Completion | 2025-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06026514
The ClinicalTrials.gov registry entry for NCT06026514 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which B/HPIV3/S-6P is the first listed.
NCT06026514 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06026514 about?
NCT06026514 is a clinical study titled "Phase I Safety Study of B/HPIV3/S-6P Vaccine Via Nasal Spray in Adults". This Phase 1 clinical trial will evaluate the safety and immunogenicity of an intranasal vaccine candidate, a recombinant, live-attenuated, bovine/human parainfluenza virus vector vaccine expressing the 6-P prefusion-stabilized version of the SARS-CoV-2 spike protein.
What is the current status of trial NCT06026514?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2023-09-18. Estimated completion is 2025-06-30.
What interventions are being tested in trial NCT06026514?
The interventions under investigation include: B/HPIV3/S-6P (BIOLOGICAL).
Who is sponsoring clinical trial NCT06026514?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.